ANO1
| Official symbol: | ANO1 |
| Full name: | anoctamin 1 |
| Location: | 11q13.3 |
| Also known as: | TAOS2, DOG1, FLJ10261, ORAOV2, TMEM16A |
| Entrez ID: | 55107 |
| Ensembl ID: | ENSG00000131620 |
| Summary: | |
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
| Gscore (Amp): | 4.28 (Driver) | | Gscore (Del): | 0.00 |
|
|
| Recurrently amplified in 3 cancer type(s) | |
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
| Total fusion occurrence: | 21 (Driver) |
|
|
| Fusions detected in 9 cancer type(s) |
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
CRISPR: STRONGLY SELECTIVE
|
|
|
| |
|
|
|
| Functional class: | Ion channel |
| JensenLab PubMed score: | 414.39 (Percentile rank: 89.39%) |
| PubTator score: | 233.44 (Percentile rank: 87.47%) |
| Target development/druggability level: | TclinThese targets have activities in DrugCentral (ie. approved drugs) with known mechanism of action. |
| Tractability (small molecule): | Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets |
| Tractability (antibody): | Predicted Tractable - High confidenceTargets located in the plasma membrane; Targets with GO cell component terms plasma membrane or secreted |
